Alto Neuroscience (ANRO)
26.62
-0.23 (0.86%)
Upcoming Events
Latest Headlines
Form SCHEDULE 13G Alto Neuroscience, Inc. Filed by: EcoR1 Capital, LLC
July 20, 2026 5:11 PM - SEC Filing
Form 8-K Alto Neuroscience, Inc. For: Jul 13
July 14, 2026 6:05 AM - SEC Filing
Form 424B5 Alto Neuroscience, Inc.
July 14, 2026 6:04 AM - SEC Filing
Alto Neuroscience prices $100M stock offering to fund depression trial
July 13, 2026 7:47 AM - StreetInsider
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
July 13, 2026 7:47 AM - BizWire
Form 8-K Alto Neuroscience, Inc. For: Jul 13
July 13, 2026 7:39 AM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Alto Neuroscience (ANRO)
June 17, 2026 6:50 AM - StreetInsider
Alto Neuroscience cites study showing pramipexole reduces anhedonia
June 15, 2026 8:03 AM - StreetInsider
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
June 15, 2026 8:03 AM - BizWire
Form 4 Alto Neuroscience, Inc. For: May 27 Filed by: Miller Andrew Craig
May 29, 2026 4:17 PM - SEC Filing
Form 3 Alto Neuroscience, Inc. For: May 27 Filed by: Miller Andrew Craig
May 29, 2026 4:16 PM - SEC Filing
Form 8-K Alto Neuroscience, Inc. For: May 27
May 28, 2026 8:18 AM - SEC Filing
Alto Neuroscience adds Karuna founder Miller to board
May 28, 2026 8:03 AM - StreetInsider
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
May 28, 2026 8:03 AM - BizWire
H.C. Wainwright Reiterates Buy Rating on Alto Neuroscience (ANRO)
May 27, 2026 6:49 AM - StreetInsider
Wolfe Research Starts Alto Neuroscience (ANRO) at Outperform
May 22, 2026 5:57 AM - StreetInsider
Alto Neuroscience (ANRO) PT Lowered to $36 at Baird
May 18, 2026 7:32 AM - StreetInsider
Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: Vestal Point Capital, LP
May 15, 2026 5:09 PM - SEC Filing
Form 4 Alto Neuroscience, Inc. For: May 14 Filed by: Etkin Amit
May 15, 2026 5:06 PM - SEC Filing
Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: Point72 Asset Management, L.P.
May 15, 2026 4:18 PM - SEC Filing
Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: Commodore Capital LP
May 15, 2026 4:13 PM - SEC Filing
Alto Neuroscience (ANRO) PT Lowered to $36 at Baird
May 15, 2026 4:08 PM - StreetInsider
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
May 15, 2026 8:27 AM - BizWire
Form SCHEDULE 13G Alto Neuroscience, Inc. Filed by: Sirenia Capital Management LP
May 15, 2026 8:08 AM - SEC Filing
Form 4 Alto Neuroscience, Inc. For: May 12 Filed by: Sanchez Ramiro
May 14, 2026 5:00 PM - SEC Filing
Form 4 Alto Neuroscience, Inc. For: May 12 Filed by: Cox Christopher Nixon
May 14, 2026 4:59 PM - SEC Filing
Form 4 Alto Neuroscience, Inc. For: May 12 Filed by: Manji Husseini
May 14, 2026 4:58 PM - SEC Filing
Form 4 Alto Neuroscience, Inc. For: May 12 Filed by: Dreyfus Andrew
May 14, 2026 4:57 PM - SEC Filing
Form 4 Alto Neuroscience, Inc. For: May 12 Filed by: York Gwill
May 14, 2026 4:56 PM - SEC Filing
Form 8-K Alto Neuroscience, Inc. For: May 12
May 13, 2026 4:21 PM - SEC Filing
Form 10-Q Alto Neuroscience, Inc. For: Mar 31
May 13, 2026 7:31 AM - SEC Filing
Form 8-K Alto Neuroscience, Inc. For: May 13
May 13, 2026 7:04 AM - SEC Filing
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026 7:03 AM - BizWire
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
May 11, 2026 4:05 PM - BizWire
BofA Securities Starts Alto Neuroscience (ANRO) at Buy
May 4, 2026 4:16 PM - StreetInsider
Alto Neuroscience reports positive Phase 2a data for depression drug
May 4, 2026 8:03 AM - StreetInsider
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
May 4, 2026 8:03 AM - BizWire
Full Article List
